GeneDx Holdings (WGS) Cost of Revenue (2020 - 2026)
GeneDx Holdings has reported Cost of Revenue over the past 7 years, most recently at $34.0 million for Q1 2026.
- Quarterly Cost of Revenue rose 18.87% to $34.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $134.8 million through Mar 2026, up 9.03% year-over-year, with the annual reading at $129.4 million for FY2025, 16.49% up from the prior year.
- Cost of Revenue was $34.0 million for Q1 2026 at GeneDx Holdings, down from $36.7 million in the prior quarter.
- Over five years, Cost of Revenue peaked at $77.7 million in Q4 2022 and troughed at $15.2 million in Q2 2023.
- The 5-year median for Cost of Revenue is $28.6 million (2025), against an average of $31.8 million.
- Year-over-year, Cost of Revenue crashed 79.97% in 2023 and then soared 294.36% in 2024.
- A 5-year view of Cost of Revenue shows it stood at $77.7 million in 2022, then crashed by 79.97% to $15.6 million in 2023, then soared by 294.36% to $61.4 million in 2024, then crashed by 40.15% to $36.7 million in 2025, then fell by 7.29% to $34.0 million in 2026.
- Per Business Quant, the three most recent readings for WGS's Cost of Revenue are $34.0 million (Q1 2026), $36.7 million (Q4 2025), and $32.2 million (Q3 2025).